Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-30
2011-08-30
Jiang, Shaojia Anna (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S049000, C514S050000, C536S026220
Reexamination Certificate
active
08008274
ABSTRACT:
The present invention provides a method of treating edematous retinal disorders. The method comprises administration of a pharmaceutical formulation comprising a hydrolysis-resistant P2Y receptor agonist to stimulate the removal of pathological extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid associated with retinal detachment and retinal edema. The P2Y receptor agonist can be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The present invention also provides a method of treating cystic fibrosis. The present invention also provides a method of treating sinusitis. The present invention further provides P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salts such as tetrasodium, tetralithium, tetrapotassium, and mixed (tetra-alkali metal) salts. The present further provides a pharmaceutical formulation comprising a P1-(2′-deoxycytidine 5′-)P4-(uridine 5′-)tetraphosphate, tetra-(alkali metal) salt, in a pharmaceutically acceptable carrier.
REFERENCES:
patent: 5837861 (1998-11-01), Pendergast et al.
patent: 6040297 (2000-03-01), De Flora et al.
patent: 6258374 (2001-07-01), Friess et al.
patent: 6277855 (2001-08-01), Yerxa
patent: 6319908 (2001-11-01), Yerxa et al.
patent: 6323187 (2001-11-01), Yerxa et al.
patent: 6348589 (2002-02-01), Pendergast et al.
patent: 6548658 (2003-04-01), Yerxa
patent: 6555675 (2003-04-01), Rideout et al.
patent: 6596725 (2003-07-01), Peterson et al.
patent: 6673779 (2004-01-01), Jacobus et al.
patent: 6696425 (2004-02-01), Yerxa et al.
patent: 6818629 (2004-11-01), Peterson et al.
patent: 6867199 (2005-03-01), Rideout et al.
patent: 6977246 (2005-12-01), Pendergast et al.
patent: 7034052 (2006-04-01), Man et al.
patent: 7078391 (2006-07-01), Peterson et al.
patent: 7223744 (2007-05-01), Yerxa et al.
patent: 7531525 (2009-05-01), Yerxa et al.
patent: WO 96/02554 (1996-02-01), None
patent: WO 96/40059 (1996-12-01), None
patent: WO 98/15563 (1998-04-01), None
patent: WO 98/34942 (1998-08-01), None
patent: WO 98/55494 (1998-12-01), None
patent: WO 00/30629 (2000-06-01), None
patent: WO 01/87913 (2001-11-01), None
patent: WO 02/060454 (2002-08-01), None
Berge et al. Journal of Pharmaceutical Sciences, 1977, 66(1), p. 1-19.
Entry for Sinusitis, WebMD, http://www.webmd.com, accessed online on Oct. 13, 2010.
Slavin, RG. Journal of Allergy and Clinical Immunology, 1988, 82(5), p. 950-956, abstract only.
Blaug, et al., “P2Y2 receptor agonists induce prolonged calcium, membrane voltage, conductance and fluid absorption increases in bovine RPE,”IOVS,41(4):S136 (2000) XP001088187.
Burnstock, et al., “P2 purinergic receptors: Modulation of cell function and therapeutic potential,”Journal of Pharmacology and Experimental Therapeutics295(3) 862-869 (2000) XP002208652.
Ferris, et al., “Oligomerization reactions of deoxyribonucleotides on montmorillonite clay: the effect of mononucleotide structure on phosphodiester bond formation,”Origins Life Evol. Biosphere,19(6):609-619 (1989) XP001085277.
Maminishkis, et al., “Purinoceptor agonists increase fluid clearance out of subretinal space (SRS) blebs in vivo,”IOVS,41(4):S136 (2000) XP001083820.
Maminishkis et al., “The P2Y2 Receptor Agonist INS37217 Stimulates RPE Fluid Transport In Vitro and Retinal Reattachment in Rat,”IOVS,43(11), 3555-3566, 2002.
Mospan, et al., “Effects of Denufosol on Sinusitis-Related Complaints in a Phase 3 Trial in Cystic Fibrosis Patients,” poster presentation; abstract #100, 32ndEuropean Cystic Fibrosis Society Conference (ECFS2009); Brest, France, Jun. 10, 2009.
Peterson, et al., “Extracellular ATP activates calcium signaling, ion, and fluid transport in retinal pigment epithelium,”Journal of Neuroscience,17:(7)2324-2337 (1997) XP001087693.
Sillero, et al., (2′,3′-Dideoxynucleoside triphosphates (ddNTP) and di-2′,3′-dideoxynucleoside tetraphosphates (ddNp4ddN) behave differently to the corresponding . . . ,Biochimica et Biophysica Acta,1334(2-3):191-199 (1997) XP002208651.
Theoclitou, et al., “Characterization of stress protein LysU. Enzyme synthesis of diadenosine 5′,5″-P1,P4-tetraphosphate (Ap4A) analogs by LysU,”J. Chem. Soc., Perkins Trans.1(16):2009-2019 (1996) XP001087969.
Williams, M., “P2 Receptors as drug discovery targets,”Am. Chem. Soc.220th, Medi-185 (2000) XP001085299.
Yerxa, et al.,J. Pharm and Experimental Therapeutics,302, 871-80, (2002).
Zhavrid, et al., “Dicytidine-5′-pyrophosphates with antivirus activity,” STN No. 123:314403, XP002208653 abstract, SU 689 202 A (Belorusskij Nauchno-Issledovatelskij Institut Epidemiologii I Mikrobio), (Oct. 30, 1993).
Pendergast William
Peterson Ward M.
Rideout Janet L.
Yerxa Benjamin R.
Inspire Pharmaceuticals Inc.
Jiang Shaojia Anna
Kung Viola T.
Lau Jonathan
Perkins Coie LLP
LandOfFree
P1-(2′-deoxycytidine 5′-)P4-(uridine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P1-(2′-deoxycytidine 5′-)P4-(uridine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P1-(2′-deoxycytidine 5′-)P4-(uridine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2663871